NewAmsterdam Pharma Company NV (NASDAQ: NAMS) open the trading on Wednesday, with a bit cautious approach as it glided -8.56% to $18.27, before settling in for the price of $19.98 at the close. Taking a more long-term approach, NAMS posted a 52-week range of $8.90-$26.35.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -28.76% for the last half of the decade. Nevertheless, stock’s Earnings Per Share (EPS) this year is 4.36%. This publicly-traded company’s shares outstanding now amounts to $92.17 million, simultaneously with a float of $42.91 million. The organization now has a market capitalization sitting at $1.69 billion. At the time of writing, stock’s 50-day Moving Average stood at $19.67, while the 200-day Moving Average is $19.48.
NewAmsterdam Pharma Company NV (NAMS) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. NewAmsterdam Pharma Company NV’s current insider ownership accounts for 53.55%, in contrast to 40.61% institutional ownership. According to the most recent insider trade that took place on Nov 18 ’24, this organization’s 10% Owner sold 33,273 shares at the rate of 25.08, making the entire transaction reach 834,440 in total value, affecting insider ownership by 11,778,760. Preceding that transaction, on Nov 15 ’24, Company’s 10% Owner sold 8,530 for 25.02, making the whole transaction’s value amount to 213,436. This particular insider is now the holder of 11,812,033 in total.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Revenue Records
NewAmsterdam Pharma Company NV’s EPS increase for this current 12-month fiscal period is 4.36% and is forecasted to reach -1.83 in the upcoming year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Let’s observe the current performance indicators for NewAmsterdam Pharma Company NV (NAMS). It’s Quick Ratio in the last reported quarter now stands at 10.61. The Stock has managed to achieve an average true range (ATR) of 1.28.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
[NewAmsterdam Pharma Company NV, NAMS] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 13.40% While, its Average True Range was 1.33.
Raw Stochastic average of NewAmsterdam Pharma Company NV (NAMS) in the period of the previous 100 days is set at 30.40%, which indicates a major rise in contrast to 4.21% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 79.87% that was higher than 57.36% volatility it exhibited in the past 100-days period.
